Immunotherapy for advanced melanoma study
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced melanoma that has spread to other parts of the body and cannot be surgically removed
- You have not had any previous treatment for advanced melanoma
- You are able to perform daily activities with little or no help (ECOG score 0-2)
- You do not have a weakened immune system or active autoimmune disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This trial studies why immunotherapy works better for some people with advanced melanoma. It looks at markers in your blood or tissue to help doctors predict who might benefit most.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.